Skip to main content

Ibex Technologies Inc(IBT-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low1.430
Day High1.430
Open:1.430
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
GlobeNewswire
IBEX Reports Results for the Second Quarter and Six Months Ended January 31, 2024
GlobeNewswire
IBEX Files Addendum to Management Proxy Circular for Sale of the Company at $1.45 Per Share
GlobeNewswire
IBEX Files Management Proxy Circular for Sale of the Company at $1.45 Per Share
GlobeNewswire
IBEX Technologies Signs Definitive Agreement for Sale of the Company for $1.45 Cash Per Share
GlobeNewswire
IBEX Reports Results for the First Quarter Ended October 31, 2023
GlobeNewswire
IBEX Reports Results for the Year Ended July 31, 2023
GlobeNewswire
IBEX Technologies Announces Renewal of Normal Course Issuer Bid
GlobeNewswire
IBEX Reports Results for the Third Quarter and the Nine Months Ended April 30, 2023
The Globe and Mail
Ibex Technologies: Top 10 Undervalued Biotechnology Industry Stocks (IBT)

Profile

Ibex Technologies Inc is a company engaged in the production and sale of diagnostic products. It manufactures and markets enzymes for biomedical use, through its subsidiaries. It also manufactures and markets a series of arthritis assays that have applications in osteoarthritis research. It sells two product lines namely, Enzymes for in-vitro diagnostics and research, and Tests for osteoarthritis research. The group provides services like Filing and lyophilization of disposable diagnostic components, and Custom fermentation and purification of enzymes for diagnostic companies. Geographically, the firm sells its products in Canada, Germany, the U.S., the U.K., and other countries of which the majority of the revenue is generated from the U.S.